Respirology

Top Medical News
POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
Audrey Abella, 5 hours ago
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).
Paleo diet focuses on high consumption of fats and low consumption of carbohydrates.
Jairia Dela Cruz, Yesterday
High adherence to the palaeolithic diet helps reduce sleep apnoea in menopausal women who are overweight, with the benefit linked to weight loss, according to a secondary analysis of a trial comparing a 2-year intervention of a palaeolithic diet with a low-fat control diet according to the Nordic Nutritional Recommendations.
Brensocatib has no impact on COVID-19 clinical outcomes
Roshini Claire Anthony, 2 days ago

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

Amantadine confers survival benefits on ICU patients with severe COVID-19
5 days ago
Treatment with amantadine appears to lower mortality among COVID-19 patients with severe respiratory failure in the intensive care unit (ICU), a retrospective study has found.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
Audrey Abella, 6 days ago
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
Add-on reslizumab cuts exacerbations, OCS use in severe eosinophilic asthma
Audrey Abella, 27 Sep 2022
Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with severe eosinophilic asthma, according to a real-world study using patient-level data from RAPSODI*.
SVS endobronchial valve improves QoL in patients with emphysema
Audrey Abella, 26 Sep 2022
In the 24-month follow-up results of the EMPROVE trial, treatment with the Spiration Valve System (SVS) endobronchial valve provided a sustained clinically significant benefit in disease-specific health-related quality of life (QoL) in patients with severe heterogeneous emphysema.
Special Reports
Product Highlight - Bilaxten ODT
16 Mar 2022
Bilastine 10 mg orodispersible tablet
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Antigen rapid tests: The new COVID-19 strategy moving forward?
Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Antigen rapid test vs RT-PCR for COVID-19: What you need to know
Pearl Toh, 29 Jul 2021
While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.
Conference Reports
Brensocatib has no impact on COVID-19 clinical outcomes
Roshini Claire Anthony, 02 Oct 2022

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

SVS endobronchial valve improves QoL in patients with emphysema
Audrey Abella, 26 Sep 2022
In the 24-month follow-up results of the EMPROVE trial, treatment with the Spiration Valve System (SVS) endobronchial valve provided a sustained clinically significant benefit in disease-specific health-related quality of life (QoL) in patients with severe heterogeneous emphysema.
Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients
Audrey Abella, 22 Sep 2022
In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.
Tezepelumab reduces mucus plugging in patients with asthma
Elaine Soliven, 22 Sep 2022
In patients with uncontrolled, moderate-to-severe asthma, tezepelumab reduced mucus plugging, which was also tied to improvements in lung function parameters, according to an exploratory post hoc analysis of the CASCADE* trial presented at ERS 2022.
Antibiotics for COPD exacerbations: Aye or nay?
Elvira Manzano, 21 Sep 2022
Antibiotics cannot be withheld in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for acute moderate exacerbations, suggests findings from the ABACOPD study presented at ERS 2022. However, in one subgroup, it appeared antibiotics can be ruled out.
Remote smoking cessation programme delivers encouraging results in high-risk individuals
Roshini Claire Anthony, 20 Sep 2022

A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.

Pirfenidone may benefit RA-ILD patients
Audrey Abella, 20 Sep 2022
In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).